What is HC Wainwright’s Forecast for Agenus FY2030 Earnings?

Agenus Inc. (NASDAQ:AGEN) – Equities researchers at HC Wainwright issued their FY2030 EPS estimates for shares of Agenus in a note issued to investors on Thursday, January 15th. HC Wainwright analyst E. Bodnar expects that the biotechnology company will post earnings of $0.34 per share for the year. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Agenus in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Agenus currently has a consensus rating of “Hold” and a consensus price target of $14.50.

Agenus Stock Performance

Shares of NASDAQ AGEN opened at $3.34 on Monday. Agenus has a 1 year low of $1.38 and a 1 year high of $7.34. The stock’s 50-day simple moving average is $3.90 and its 200-day simple moving average is $4.42. The firm has a market cap of $113.59 million, a price-to-earnings ratio of -1.57 and a beta of 1.58.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported $1.94 earnings per share for the quarter, missing analysts’ consensus estimates of $2.63 by ($0.69). The business had revenue of $30.24 million for the quarter, compared to the consensus estimate of $80.39 million.

Institutional Trading of Agenus

Several hedge funds and other institutional investors have recently bought and sold shares of AGEN. Vanguard Group Inc. lifted its holdings in Agenus by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,569,533 shares of the biotechnology company’s stock worth $9,893,000 after buying an additional 36,983 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Agenus by 3,080.3% during the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after acquiring an additional 427,604 shares in the last quarter. Marshall Wace LLP bought a new position in Agenus during the second quarter worth $1,976,000. Bank of America Corp DE boosted its holdings in Agenus by 110.0% in the second quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock worth $1,922,000 after purchasing an additional 220,327 shares during the period. Finally, Walleye Capital LLC bought a new stake in Agenus during the second quarter valued at $906,000. 61.46% of the stock is owned by institutional investors.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.